Results 51 to 60 of about 494,085 (317)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force [PDF]
, 2013 Background: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective: To define the treatment
Baraliakos, Xenofon +31 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective This study investigated whether sleep disturbance can predict the extent to which pain interferes with daily functioning in patients with early rheumatoid arthritis (RA). Methods Data were from adults with early RA (joint symptoms ≤12 months) enrolled in the Canadian Early Arthritis Cohort between 2016 and 2023.
Burcu Aydemir +16 more
wiley +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, EarlyView.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]
, 2019 Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M +4 more
core
Journal of Clinical Medicine, 2020 In a subset of psoriasis (PsO) and psoriatic arthritis (PsA) patients, the skin and/or joint lesions appear to generate biologically significant systemic inflammation. Red cell distribution width (RDW) and mean platelet volume (MPV) are readily available
R. Conic +7 more
semanticscholar +1 more source
Advanced Science, EarlyView.This study defines the structure, mechanics, and mechanobiology of the fibrocartilage pericellular matrix (PCM) using the murine meniscus, showing how collagen V deficiency alters PCM properties and disrupts cell mechanosensitive signaling. Findings emphasize the critical role of PCM in fibrocartilage mechanobiology and suggest targeting it can enhance
Chao Wang +13 more
wiley +1 more source
The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study [PDF]
, 2017 Background: In this study, we sought to compare the performance of spondyloarthritis (SpA) classification criteria sets in an international SpA cohort with patients included from five continents around the world.
Bakker, Pauline +7 more
core +2 more sources
JAMA dermatology, 2020 This pooled cohort study evaluates the safety of newer biological agents for the treatment of tuberculosis infection and activation in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
B. Elewski +13 more
semanticscholar +1 more source
Pinosylvin Inhibits Inflammatory and Osteoclastogenesis via NLRP3 Inflammasome
Advanced Science, EarlyView.Pinosylvin blocks LPS and RANKL induced NEK7/NLRP3 interaction, inhibiting NLRP3 inflammasome oligomerization and assembly, reducing IL‐1β maturation and GSDMD cleavage, and improving the inflammatory microenvironment and abnormal osteoclastogenesis. Abstract Pro‐inflammatory cytokines such as TNF, IL‐1, and IL‐6 trigger aberrant osteoclastogenesis and
Wei Zhang +13 more
wiley +1 more source
Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis [PDF]
, 2016 Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of comorbidities.
Cavaliere, Arturo +2 more
core +2 more sources